Latest Breaking News On - Matthias dobbelstein - Page 1 : comparemela.com

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

/PRNewswire/ Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I).

Israel generalAmir reichmanMatthias dobbelsteinTamar ben yedidiaJoshua phillipsonScinai immunotherapeuticsMax planck institute for multidisciplinary sciencesCompany contactAntiviral researchPrnewswire scinai immunotherapeutics ltdUniversity medical centerScinai immunotherapeutics ltdMax planck instituteMultidisciplinary sciencesHeinz maier leibnitz prizeAlfried krupp prize

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Data backs use of Scinai s aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, addressing significant medical needs JERUSALEM, Dec. 11, 2023 /PRNewswire/.

Israel generalScinai nanoabsMatthias dobbelsteinJoshua phillipsonAmir reichmanMax planckScinai immunotherapeuticsTamar ben yedidiaScinai bioservicesScinai immunotherapeutics ltdMax planck societyExchange commissionCompany annual report on formIsraeli innovation authorityUniversity medical centerCompany contact

Biomednewsbreaks Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting Nanoabs

Biomednewsbreaks Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting Nanoabs
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesMatthias dobbelsteinScinai immunotherapeuticsTamar ben yididiaLife sciencesScinai immunotherapeutics ltdBiomedical sciences biomedAntiviral researchMax planck institute for multidisciplinary sciencesMenafn investor brand network scinai immunotherapeuticsUniversity medical center goBrand networkMax planck instituteMultidisciplinary sciencesBiomedical sciences

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

JERUSALEM, April 17, 2023 via InvestorWire BiondVax Pharmaceuticals Ltd. , a biotechnology company focused on developing, manufacturing, and commercializing innovative. | April 17, 2023

Israel generalUnited statesAmir reichmanLos angelesMatthias dobbelsteinBiondvax nanoabEuropean investment bankPharmaceuticals ltdExchange commission onGlobenewswire incMax planck societyCompany annual report on formUniversity medical centerExchange commissionResearch collaborationBiondvax pharmaceuticals ltd

BiondVax Pharmaceuticals Ltd : BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) via InvestorWire BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative

Israel generalUnited statesLos angelesMatthias dobbelsteinBiondvax nanoabAmir reichmanResearch collaborationMax planck societyCompany scientific advisory boardEuropean investment bankCorporate communicationsBiondvax pharmaceuticals ltdExchange commissionInstitute of molecular oncologyUniversity medical centerMax planck institute for multidisciplinary sciences